Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00114686
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2005-06-16
Brief Title:
Efficacy and Safety of Quetiapine Fumarate SEROQUEL in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multicenter Randomized Placebo-Controlled Parallel-Group Double-Blind Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate SEROQUEL Versus Placebo as Adjunct Therapy With Mood Stabilizers Lithium or Divalproex for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether treatment with Quetiapine Fumarate SEROQUEL in conjunction with mood stabilizers Lithium or Divalproex for 12 weeks helps patients who have Bipolar I Disorder with Alcohol Dependence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None